Reply

dc.authorscopusid9736176600
dc.authorscopusid7004457653
dc.contributor.authorGürlü V.P.
dc.contributor.authorDemir M.
dc.date.accessioned2024-06-12T10:25:21Z
dc.date.available2024-06-12T10:25:21Z
dc.date.issued2009
dc.description.abstract[No abstract available]en_US
dc.identifier.doi10.1097/ICO.0b013e31818754bf
dc.identifier.issn0277-3740
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-67650584200en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage123en_US
dc.identifier.urihttps://doi.org/10.1097/ICO.0b013e31818754bf
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16282
dc.identifier.volume28en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofCorneaen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFresh Frozen Plasma; Heparin; Plasminogen; Conjunctivitis; Disease Severity; Heterozygosity; Homozygosity; Human; Letter; Ligneous Conjunctivitis; Plasminogen Type I Deficiency; Priority Journal; Protein Deficiency; Treatment Outcomeen_US
dc.titleReplyen_US
dc.typeLetteren_US

Dosyalar